

WE CLAIM:

1. An anastomosis stent for insertion into an opening in a lumen of a vessel or tissue of a patient, comprising:
a first terminus;
a second terminus;
an opening at each terminus; and
a primary lumen providing fluid communication between the openings at the first and second termini,

wherein at least one of the first and second termini is sized to be inserted into an opening in a vessel of a patient, and the stent is comprised of a non-polyglycolic acid material that is resorbable by the patient in about a few minutes up to about 90 days.

2. The stent of claim 1, wherein the primary lumen is substantially straight.

3. The stent of claim 1, wherein the primary lumen is curved, bent, or both.

4. The stent of claim 1, wherein at least one of the first and second termini is tapered or shaped.

5. The stent of claim 1, further comprising a flange at one of the first and second termini.

6. The stent of claim 1, wherein at least one of the first and second termini has a diameter of about 1 mm to about 10 mm.

7. The stent of claim 6, wherein the diameter is about 1 mm to about 8 mm.

8. The stent of claim 1, wherein the first and second termini have different diameters.

9. The stent of claim 1, wherein the termini are located about 1 cm to about 5 cm apart.

5 10. The stent of claim 9, wherein the termini are located at about 1.5 cm to about 4 cm apart.

11. The stent of claim 10, wherein the termini are located about 2 cm to about 3 cm apart.

10

12. The stent of claim 1, wherein at least one of the first and second termini is sized for anastomotic insertion into a blood vessel of the patient.

13. The stent of claim 12, wherein the blood vessel is an artery.

15

14. The stent of claim 13, wherein the artery is a coronary artery.

15. The stent of claim 13, wherein the artery is the patient's aorta.

20

16. The stent of claim 12, wherein the blood vessel is a vein of the patient.

17. The stent of claim 1, further comprising a third terminus and a third opening at the third terminus, wherein the third opening is in fluid communication with the primary lumen through an intersecting lumen.

25

18. The stent of claim 17, wherein the primary and intersecting lumens intersect at point closer to the first terminus than to the second terminus

30

19. The stent of claim 17 wherein the primary and intersecting lumens intersect perpendicularly.

20. The stent of claim 17, wherein the primary and intersecting lumens intersect non-perpendicularly.

5 21. The stent of claim 1, wherein the material is resorbable by the patient in about a few minutes to about ten days.

22. The stent of claim 21, wherein the material is resorbable by the patient in about seven days to about ten days.

10

23. The stent of claim 21, wherein the material is resorbable by the patient in about one day to about seven days.

15

24. The stent of claim 23, wherein the material is resorbable by the patient in about one day to about two days.

25. The stent of claim 1, wherein the material comprises frozen physiologic saline.

20

26. The stent of claim 1, wherein the material comprises a hydrophilic compound.

27. The stent of claim 1, wherein the hydrophilic compound comprises a polyethylene glycol-containing compound.

25

28. The stent of claim 27, wherein the polyethylene glycol-containing compound comprises a polyethylene glycol that is chemically conjugated with a naturally occurring compound.

30

29. The stent of claim 28, wherein the naturally occurring compound is a protein.

Amended
Q2

30. The stent of claim 29, wherein the protein is a collagenic material.

31. The stent of claim 30, wherein the collagenic material is a gelatin.

32. The stent of claim 30, wherein the collagenic material is selected from the group consisting of type I, type II, and type III collagens, and combinations thereof.

33. The stent of claim 27, wherein the naturally occurring compound is a polysaccharide.

34. The stent of claim 32, wherein the polysaccharide is selected from the group consisting of hyaluronic acid, cyclodextrin, hydroxymethylcellulose, cellulose ether, and starch.

35. The stent of claim 27, wherein the naturally occurring compound is a glycosaminoglycan or a proteoglycan.

36. The stent of claim 27, wherein the polyethylene glycol has a molecular weight of about 100 to about 20,000 daltons.

37. The stent of claim 26, wherein the hydrophilic material is comprises a collagenic material.

38. The stent of claim 37, wherein the collagenic material comprises a collagen that is chemically conjugated to a synthetic hydrophilic polymer.

39. The stent of claim 38, wherein the synthetic hydrophilic polymer is selected from the group consisting of polyethylene glycol and polyvinylpyrrolidone.

5

15

20

25

30

40. The stent of claim 1, further comprising a tissue sealant on a surface thereof.

41. A method of anastomosis comprising the step of:

(a) inserting the first terminus of the stent of claim 1 through an aperture into the cavity of a physiologically functioning vessel of a patient, and the second terminus of the stent into a conduit, such that an interface is formed between the vessel and the conduit about the aperture; and

(b) attaching the vessel to the conduit at the interface.

42. A method of anastomosis comprising the step of:

(a) inserting the first and second termini of the stent of claim 17 through in a physiologically functioning vessel of a patient, and the third terminus of the stent into a bypass conduit, such that an interface is formed between the vessel and the bypass conduit about the aperture; and

(b) attaching the vessel to the bypass conduit at the interface.


43. The method of claim 42, wherein step (b) is carried out without need for a suture.

44. The method of claim 42, wherein step (b) comprises (b') introducing a tissue sealant around or over the interface between the vessel and the bypass conduit.

45. The method of claim 44, wherein the sealant comprises a collagenic material.

46. The method of claim 45, wherein the collagenic material comprises a methylated collagen.

47. The method of claim 45, wherein the collagenic material is selected from the group consisting of CIS, CSF, and combinations thereof.

30


48. The method of claim 44, wherein the sealant comprises a polyethylene glycol.

49. The method of claim 48, wherein the polyethylene glycol is selected from the group consisting of polyethylene glycol di-succinimidyl glutarate, pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate, polyethylene glycol ether tetra-succinimidyl glutarate, polyethylene glycol mono-succinimidyl succinate, polyethylene glycol mono-succinimidyl propionic acid, polyethylene glycol mono-succinimidyl succinamide, polyethylene glycol di-succinimidyl succinamide, polyethylene glycol di-epoxide, polyethylene glycol di-isocyanate, polyethylene glycol di-carbonyldiimidazole, pentaerythritol polyethylene glycol ether tetra-maleimidopropionamide, pentaerythritol polyethylene glycol ether tetra-malimidopropionate, polyethylene glycol di-amine, diglycero polyethylene glycol ether tetra-amine, pentaerythritol polyethylene glycol ether tetra-amine, polyethylene glycol di-sulfhydryl, pentaerythritol polyethylene glycol ether tetra-sulfhydryl, pentaerythritol polyethylene glycol ether, diglycerol poly(ethylene glycol) ether, combinations thereof, and copolymers thereof

50. The method of claim 44, wherein step (b) further comprises, after step (b'), (b'') crosslinking the sealant.

51. The method of claim 44, wherein the tissue sealant is injected around or over the interface.

52. The method of claim 44, wherein the tissue sealant is applied as a spray.

53. The method of claim 42, wherein steps (a) and (b) are carried out simultaneously.

54. A tissue plug for use in sealing an opening in a patient's tissue, comprising a solid object having a platen surface, which is adapted to cover the opening, contact the

perimeter about the opening, or both; wherein the solid object is comprised of a non-polyglycolic acid material that is resorbable by the patient in a maximum of about 90 days.

5 55. The plug of claim 54, further comprising a tissue sealant on a surface thereof.

56. The plug of claim 54, wherein the platen surface is supported by a pedestal structure having a pedestal lateral dimension.

10 57. The plug of claim 56, wherein the platen surface has a lateral dimension equal to the pedestal structure lateral dimension.

58. The plug of claim 56, wherein the platen surface has a lateral dimension greater than the pedestal structure lateral dimension.

15 59. The plug of claim 54, wherein the platen surface is nonplanar.

60. The plug of claim 54, wherein the platen surface is shaped to conform to the lumen surface of a blood vessel of the patient.

20 61. The plug of claim 60, wherein the blood vessel is an artery.

62. The plug of claim 61, wherein the artery is a coronary artery.

25 63. The plug of claim 60, wherein the blood vessel is the patient's aorta.

64. The plug of claim 54, wherein said resorbable material is selected from the group consisting of saline, polyethylene glycol, and blood plasma.

65. The plug of claim 54, wherein the material is resorbable by the patient in about one day to about ten days.

5 66. The plug of claim 65, wherein the material is resorbable by the patient in about seven days to about ten days.

67. The plug of claim 65, wherein the material is resorbable by the patient in about one day to about seven days.

10 68. The plug of claim 67, wherein the material is resorbable by the patient in about one to about two days.

69. The plug of claim 54, wherein the material comprises a hydrophilic compound.

15 70. The plug of claim 54, wherein the hydrophilic compound comprises a polyethylene glycol-containing compound.

20 71. The plug of claim 70, wherein the polyethylene glycol-containing compound comprises a polyethylene glycol that is chemically conjugated with a naturally occurring compound.

72. The plug of claim 71, wherein the naturally occurring compound is a protein.

25 73. The plug of claim 72, wherein the protein is a collagenic material.

74. The plug of claim 73, wherein the collagenic material is a gelatin.

30 75. The plug of claim 73, wherein the collagenic material is selected from the group consisting of type I, type II, and type III collagens, and combinations thereof.

76. The plug of claim 71, wherein the naturally occurring compound is a polysaccharide.

5 77. The plug of claim 76, wherein the polysaccharide is selected from the group consisting of hyaluronic acid, cyclodextrin, hydroxymethylcellulose, cellulose ether, and starch.

10 78. The plug of claim 71, wherein the naturally occurring compound is a glycosaminoglycan or a proteoglycan.

15 79. The plug of claim 70, wherein the polyethylene glycol has a molecular weight of about 100 to about 20,000 daltons.

20 80. The plug of claim 69, wherein the hydrophilic material is a collagenic material.

25 81. The plug of claim 80, wherein the collagenic material comprises a collagen that is chemically conjugated to a synthetic hydrophilic polymer.

 82. The plug of claim 81, wherein the synthetic hydrophilic polymer is selected from the group consisting of polyethylene glycol and polyvinylpyrrolidone.

 83. A method of sealing an opening in a patient's tissue comprising the steps of:
 (a) positioning the plug of claim 54 in relationship to an opening in a patient's tissue, such that the plug covers the opening, contacts the perimeter about the opening, or both, thereby forming an interface between the plug and the tissue; and
 (b) adhering the patient's tissue to the plug to form a closure.

84. The method of claim 83, wherein step (b) comprises (b') introducing a tissue sealant around or over the interface.

85. The method of claim 84, wherein the sealant comprises a collagenic material.

86. The method of claim 85, wherein the collagenic material is a PEG-collagen.

87. The method of claim 84, wherein the sealant comprises polyethylene glycol.

88. The method of claim 84, wherein step (b) further comprises, after step (b'), (b'') crosslinking the sealant.

89. The method of claim 84, wherein the tissue sealant is applied through injection.

90. The method of claim 84, wherein the tissue sealant is applied as a spray.

91. The method of claim 83, wherein steps (a) and (b) are carried out simultaneously.

92. The method of claim 83, further comprising, after step (a), (b') placing additional tissue in contact with the plug, such that the plug is interposed between the additional tissue and the tissue associated with the opening.

93. The method of claim 92, further comprising, after (b'), adhering the additional tissue to the tissue associated with the opening.

94. A sutureless method of anastomosis comprising the steps of:
(a) providing a stent comprising a first terminus, a second terminus, a third terminus, an opening at each terminus that fluidly communicate with each other through

Amended
30

the interior of the stent, wherein the stent is comprised of a non-polyglycolic acid material that is resorbable by a patient in up to about 90 days;

(b) inserting the first and second termini of the stent through an aperture into a cavity of a physiologically functioning vessel of a patient, and the third terminus of the stent into a conduit, such that an interface is formed between the vessel and the by pass conduit about the aperture; and

(c) applying a tissue sealant at the interface to attach the conduit to the vessel.

95. A sutureless method of sealing an opening in a patient's tissue comprising the steps of:

(a) providing a plug comprised of a solid non-polyglycolic acid material that is resorbable by the patient in a maximum of about 90 days;

(b) positioning the plug in relationship to an opening in a patient's tissue, such that the plug covers the opening, contacts the perimeter about the opening, or both, thereby forming an interface between the plug and the tissue; and

(c) applying a resorbable sealant at the interface to form a closure.

96. A sutureless method of anastomosis comprising the steps of:

(a) providing a stent comprising a first terminus, a second terminus, a third terminus, an opening at each terminus that fluidly communicate with each other through the interior of the stent, wherein the stent is comprised of material that is resorbable by a patient in up to about 90 days;

(b) inserting the first and second termini of the stent through an aperture into a cavity of a physiologically functioning vessel of a patient, and the third terminus of the stent into a conduit, such that an interface is formed between the vessel and the by pass conduit about the aperture; and

(c) applying a tissue sealant at the interface to attach the conduit to the vessel such that the interface exhibits a tensile strength of at least about 1.3N/cm².